CDK7 and cancer: Cancer studies on CDK7 gained momentum upon discovery of the covalently binding inhibitor THZ1 that blocks growth of various cancer entities, among them triple negative breast cancer, Myc-associated tumors, non-small cell lung carcinoma and also pancreatic cancer [23,58].